Web Results

Erik Cline | LinkedIn


... Vyvanse B.E.D., Neuroscience Business Unit at Shire Pharmaceuticals .... Coach/Owner at E. Cline Development Coaching LLC ... Head of ADHD Marketing at Neos Therapeutics, Inc. ... u · v · w · x · y · z · more; Browse members by country.

Christopher Janssen | LinkedIn


Shire Pharmaceuticals ... •Responsible for reviewing actual vs. planned results, performing variance analyses ... Principal Analyst / Design Specialist at Avastone Technologies, LLC ... Head of Insights and Execution at Neos Therapeutics, Inc.

Neos Therapeutics Announces Trade Name Cotempla XR-ODT ...


May 20, 2015 ... Neos Therapeutics, Inc. Announces Settlement of Pending Patent Litigation ... its Amphetamine Polistirex XR-ODT (NT-0202) with Shire LLC.

Response/Remission With Guanfacine Extended-Release and ...


Aug 14, 2014 ... ... more participants in both GXR + psychostimulant groups versus the ... Shire provided funding to SCI and MedErgy for support in writing and editing this manuscript. ... Neos Therapeutics, Neuroscience Education Institute, Neurovance , ... of Shire; he is currently an employee of Alcobra Inc. Ms. White was a ...

Five things to consider before buying Neos Therapeutics stock ...


Jul 21, 2015 ... (Source: Neos Therapeutics Inc ) Company to Hold First Quarterly Call as a .... its Amphetamine Polistirex XR-ODT (NT-0202) with Shire LLC.

Efficacy of Guanfacine Extended Release Assessed During the ...


Therefore, children with ADHD may have a need for long-lasting therapeutic options .... Shionogi Inc., and Shire; speakers bureaus for Bristol-Myers Squibb, Eli Lilly and ... Enzymotec, GencoSciences, Neos Therapeutics, Shire, and Sunovion. ... Banaschewski T., Roessner V., Dittmann RW., Santosh PJ., Rothenberger A.: ...

Participant-Perceived Quality of Life in a Long-Term, Open-Label ...


Participants with baseline self-perceived poor QOL (n=32) versus all others ..... Dr . Thomas Babcock, from Shire Development LLC, also reviewed and edited the ... LLC, Little Rock, AR; Valley Clinical Research, Inc., El Centro, CA; Peninsula ... Lilly, Neo Therapeutics, NextWave, Novartis, Noven, Ortho-McNeil-Janssen, ...

Attention Deficit Hyperactivity Disorder Comparative Analysis ...


Jul 30, 2015 ... ... an overview of the Attention Deficit Hyperactivity Disorder therapeutic pipeline. ... Inc., Mnemosyne Pharmaceuticals, Inc., Neos Therapeutics, Inc., ... Shire Plc, Signature Therapeutics, Inc, Sunovion Pharmaceuticals Inc., ... TAK-137, TRI-102 , V-81444, viloxazine hydrochloride, vortioxetine hydrobromide.

Forum Leadership - Massachusetts Biotechnology Council


Maurizio V. Cattaneo, Founder & CEO, BioVolutions, Inc. Gerry Cox, ... Berg; Masha Hareli, PhD, Founder & President, ATR, LLC; Steve Riesinger, PhD, ... Food and Drug Administration; Alex Nivorozhkin, PhD, Co-Founder & COO, Neo- Advent ... Mladen Bozic, Senior Director, Global Regulatory Policy & Intelligence, Shire ...

72x48 Poster Template - Neurovance


Data on file (Centanafadine SR Clinical Study Report), Neurovance Inc., Cambridge, ... the exact timing of the centanafadine SR vs. placebo treatment to maintain .... Timothy Wilens, MD: Grant support: NIH (NIDA) and Shire; Consultant: ... Johnson & Johnson Pharmaceutical Research & Development, Lilly USA, LLC, Neos.

Helpful Resources

Shire Sues Neos To Block Adderall XR Competitor - Law360


Apr 12, 2013 ... The case is Shire LLC v. Neos Therapeutics, Inc., case number 3:13-cv-01452, in the U.S. District Court for the Northern District of Texas.

Shire sues Neos Therapeutics in Adderall patent dispute - Dallas ...


Apr 15, 2013 ... A U.S. affiliate of the Irish biopharmaceutical giant Shire plc has sued Grapevine- based Neos Therapeutics Inc. in an attempt to block it from ...

News-Events | Neos Therapeutics


Neos Therapeutics Announces Second Quarter 2015 Financial Results ... Neos Therapeutics, Inc. Appoints Thomas P. McDonnell as Chief Commercial Officer

Jake Freed - Professionals - Davis Wright Tremaine


Shire LLC v. Neos Therapeutics, Inc.*. Represented patentee in Hatch-Waxman litigation relating to ADDERALL XR patents. (N.D. Tex. 2014) ...

IPO Report: Neos Therapeutics (NEOS) - Equities.com - Global ...


Jul 22, 2015 ... Neos Therapeutics (NEOS) is a pharmaceutical company focused on ... including Shire (Vyvanse, Adderall XR, Intuniv), Janssen (Concerta), ... Entities affiliated with CAC, LLC 9.15% ..... Coordinated Multi-Point (CoMP) v